Zydus Lifesciences Receives USFDA Approval to Start Phase III Trial of Sickle Cell Anaemia Drug With ICMR
Key Takeaways
- •Zydus Lifesciences and ICMR have received USFDA approval to commence a Phase III clinical trial for their sickle cell anaemia drug candidate.
- •The Phase III trial follows a jointly conducted Phase II proof-of-concept study that met its primary endpoint and demonstrated positive efficacy and safety outcomes.
- •Sickle cell anaemia is an inherited blood disorder that causes red blood cells to become rigid and sickle-shaped, leading to reduced oxygen delivery and complications.
- •The Phase III trial will evaluate the treatment candidate in a larger patient population to gather further evidence on safety and effectiveness before potential regulatory submission.
Zydus Lifesciences has received approval from the US Food and Drug Administration (USFDA) to begin a Phase III clinical trial of a drug candidate for the treatment of sickle cell anaemia in collaboration with the Indian Council of Medical Research (ICMR).
The company said the approval follows the successful completion of a Phase II proof-of-concept trial conducted jointly by Zydus and ICMR. According to Zydus, the Phase II study met its primary endpoint and showed positive efficacy and safety outcomes.
Sickle cell anaemia is an inherited blood disorder that affects haemoglobin, the protein in red blood cells that carries oxygen through the body. The condition can cause red blood cells to become rigid and sickle-shaped, reducing oxygen delivery and contributing to complications such as pain episodes and anaemia. Phase III clinical trials are typically designed to evaluate a treatment in a larger patient population and provide additional evidence on safety and effectiveness before a potential regulatory submission.
The development marks the next stage of clinical testing for the Zydus-ICMR programme after the reported Phase II results. The larger study will be an important step in determining whether the candidate can generate the clinical evidence required for further regulatory review.
